FDA Publishes Guidance Documents to Enhance Supply Chain Security
The agency issued two final and two draft guidance documents to help identify and trace drug products in the supply chain.
FDA published guidance documents on June 3, 2021, that provide recommendations for complying with the Drug Supply Chain Security Act (DSCSA) in order to identify and trace drug products as they move through the supply chain. Two final guidance documents and two draft guidance documents were issued.
Product Identifiers Under the Drug Supply Chain Security Act, Questions and Answers clarifies the DSCSA requirement that manufacturers and repackagers put a product identifier on drug packages that includes a national drug code, serial number, lot number, and expiration date.
Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification offers certain trading partners aid in identifying a suspect product. It also describes how to notify FDA of illegitimate products.
Definitions of Suspect Product and Illegitimate Product for Verification Obligation under DSCSA describes terms used to define “suspect” and “illegitimate” products and revises the March 2018 draft guidance, and Enhanced Drug Distribution Security at the Package Level under DSCSA details requirements for enhanced drug distribution security at the package level and provides recommendations on the system attributes necessary for secure tracing of product at the package level.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
